Experts shared diagnosis and management strategies for chronic pruritus at the Dermatology Days of Paris 2024 conference.

Fatty liver disease, often associated with excessive alcohol consumption and poor diet, has been widely recognized for its ...

Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

The combination of brain radiotherapy and chemoimmunotherapy “resulted in promising intracranial and systemic anti-tumor activity, with a manageable safety profile,” researchers wrote.

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) for the treatment of adults with locally advanced ...

Xerosis is the most common cause of pruritus without an accompanying rash, and it can be associated with inflammatory skin diseases including atopic dermatitis, systemic diseases such as ...

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...

TRAEs of any grade that were more common in the nivolumab-ipilimumab arm than in the chemotherapy arm included pruritus (22% and 5%), hypothyroidism (16% and 0%), rash (10% and 8%), alanine ...

Novocure today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival ...

Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...